QBIO Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (18 bal. 2024 @ 21:32):

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies...

Stats
Dzisiejszy wolumen	1 123.00
Średni wolumen	23 222.00
Kapitalizacja rynkowa	29 019.00
EPS	$0 ( 2024-03-13 )
Następna data zysków	( $0 ) 2024-05-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0100
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2022-05-26	Corin Denis	Buy	200 000	Common Stock
2021-02-01	Rosenstadt William S	Buy	35 000	Common stock
2020-10-27	Corin Denis	Buy	500 000	Incentive Stock Options
2020-08-29	Corin Denis	Buy	150 000	Incentive Stock Options
2020-08-29	Corin Denis	Buy	150 000	Incentive Stock Options

INSIDER POWER
100.00
Last 100 transactions
Buy: 7 488 702 \| Sell: 150 251

Q BioMed Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Q BioMed Inc. Finanse

Annual	2022
Przychody:	$284 352
Zysk brutto:	$-8 988.00 (-3.16 %)
EPS:	$-0.0160

FY	2022
Przychody:	$284 352
Zysk brutto:	$-8 988.00 (-3.16 %)
EPS:	$-0.0160

FY	2021
Przychody:	$195 597
Zysk brutto:	$-51 249.00 (-26.20 %)
EPS:	$-0.298

FY	2020
Przychody:	$30 000.00
Zysk brutto:	$-296 009 (-986.70 %)
EPS:	$-0.650

Financial Reports:

No articles found.

Q BioMed Inc.

Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride SR89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, a pre-clinical lead candidate for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutics to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.